Found 419 clinical trials
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.
) following progression on EGFR Tyrosine Kinase Inhibitors.. Study population: Individuals may be eligible to enrol in this trial if aged 18 or over and have been diagnosed with advanced non
- 27 views
- 24 Jan, 2021
- 16 locations
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective studies. Recently the FDA approved
- 0 views
- 07 Jun, 2021
- 39 locations
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer
in subjects with advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations who have progressed while on treatment with an EGFR tyrosine kinase inhibitor (TKI) agent (other lines of
- 51 views
- 30 Jan, 2021
- 10 locations
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations are exquisitely sensitive to epidermal growth factor receptor tyrosine kinase
- 3 views
- 08 Nov, 2020
- 1 location
The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA
disability. Tofacitinib(TF) is a new type of oral tyrosine kinase inhibitor (JAKi) for the treatment of moderate to severe active RA. However, there is alack of Chinese data on the joint scheme, long-term
- 0 views
- 26 Jun, 2021
- 1 location
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
as ZD1839) and erlotinib (Tarceva ®, formerly known as OSI-774). Both are small molecule orally-bioavailable tyrosine kinase inhibitors (TKIs) of the EGFR TK domain, and have been shown to
- 39 views
- 07 Nov, 2020
- 1 location
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
, thus enhancing immune response and has potential to treat various types of tumors. As a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signalinganlotinib is
- 1 views
- 23 Jan, 2021
- 1 location
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
experience significantly varying duration of response and survival rate. Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of
- 1 views
- 23 Jan, 2021
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib
- 0 views
- 26 Jan, 2021
- 30 locations
Study in Patients With Chronic Leukemia Where Previous Therapy Failed and Who Will be Treated With Ponatinib as Second Line Therapy
This study will include patients suffering from chronic myeloid leukemia (CP-CML), who were treated with tyrosine kinase inhibitor (TKI, a substance that blocks the action of enzymes) in a
- 0 views
- 15 May, 2021
- 10 locations